CARM Carisma Therapeutics
- 0.441
- +0.022+5.18%
Carisma Therapeutics News
Carisma Therapeutics Appoints Interim VP of Finance
Express News | Carisma Therapeutics Inc: On Dec 24, Appoints Natalie Mcandrew as Principal Financial Officer
H.C. Wainwright Downgrades Carisma Therapeutics(CARM.US) to Hold Rating
Express News | HC Wainwright & Co. Downgrades CARISMA Therapeutics to Neutral
Carisma Downgraded by Baird Over Lack of Near-term Catalysts
Express News | D. Boral Capital Maintains Buy on CARISMA Therapeutics, Maintains $12 Price Target
Carisma Therapeutics Price Target Cut to $1.00/Share From $10.00 by Baird
Baird Downgrades Carisma Therapeutics(CARM.US) to Hold Rating, Cuts Target Price to $1
BTIG Maintains Carisma Therapeutics(CARM.US) With Hold Rating
Carisma Therapeutics: Hold Rating Amid Strategic Shift and Uncertain Pipeline Prospects
Express News | Carisma Therapeutics Inc : Baird Cuts to Neutral Rating; Cuts Target Price to $1 From $10
Carisma Therapeutics Cut to In-Line From Outperform by Evercore ISI Group
Carisma Therapeutics Price Target Cut to $0.70/Share From $4.00 by Evercore ISI Group
Evercore Downgrades Carisma Therapeutics(CARM.US) to Hold Rating, Cuts Target Price to $0.7
Carisma Therapeutics Cut to Neutral From Buy by BTIG
BTIG Downgrades Carisma Therapeutics(CARM.US) to Hold Rating
BTIG Downgrades Carisma Therapeutics (CARM) to a Hold
Express News | Carisma Therapeutics Inc - Chief Financial Officer, Richard Morris Will Leave Company Effective Dec 31
Express News | Carisma Therapeutics Inc -Development of Ct-0525 to Be Discontinued; Workforce Reduced by 34%
Express News | Carisma Therapeutics Announces Strategic Restructuring to Re-Prioritize Pipeline
No Data